I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Fluorescein Angiography for Age-Related Macular Degeneration
Understanding Fluorescein Angiography
Fluorescein angiography is a retinal imaging procedure with a long track record in ophthalmology. It remains one of the most informative tests available for evaluating the blood vessels inside the eye, especially in the setting of AMD.
Fluorescein angiography is a diagnostic imaging procedure that maps the blood vessels in your retina and in the layer beneath it called the choroid. During the test, a small amount of fluorescein dye is injected into a vein in your arm. As the dye travels through the blood vessels in your eye, a specialized camera takes a rapid series of photographs. These images show how blood flows through the retina and whether any vessels are leaking or growing in abnormal ways.
The test typically takes about 10 to 15 minutes from start to finish. The resulting images give your specialist a detailed, real-time view of vascular health at the back of your eye, a level of detail that other imaging tools cannot fully replicate on their own.
Fluorescein dye glows when exposed to a specific wavelength of blue light. As the dye passes through the retinal blood vessels, the camera captures this glow at different time points throughout the test.
Healthy blood vessels contain the dye within their walls. Abnormal blood vessels lack the tight cell junctions that normally prevent leakage, so the dye seeps out into surrounding tissue. Your specialist examines the images in phases. Early-phase images show the dye arriving in the retinal arteries and spreading through smaller vessels. Late-phase images, taken several minutes later, reveal whether dye has pooled outside the vessel walls. This leakage pattern is what allows our specialists to identify choroidal neovascularization (CNV), meaning abnormal new blood vessel growth beneath the retina, which is the defining feature of wet AMD.
Optical coherence tomography (OCT) is another imaging test commonly used in AMD care. OCT creates detailed cross-sectional images of the retinal layers and is excellent at detecting fluid buildup and measuring retinal thickness. However, OCT does not directly show whether blood vessels are leaking or identify the specific source of that leakage.
Fluorescein angiography and OCT provide complementary information, and both play important roles in evaluating AMD. While OCT has become the preferred tool for routine monitoring because it is noninvasive and fast, fluorescein angiography remains essential for classifying AMD, particularly when wet AMD is suspected or when OCT findings alone are not enough to guide a treatment decision.
Why Fluorescein Angiography Matters in AMD
AMD exists in two main forms, each requiring a different approach to management. Fluorescein angiography helps our specialists determine which form is present and provides the detail needed to plan effective treatment.
Dry AMD involves the gradual breakdown of light-sensitive cells in the macula, the central part of the retina responsible for sharp, detailed vision. Wet AMD occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, causing rapid and potentially severe vision loss.
Fluorescein angiography is one of the most valuable tools for distinguishing between these two forms and for identifying the specific pattern of abnormal vessel growth in wet AMD. This distinction directly shapes the treatment plan and how urgently intervention may be needed.
Choroidal neovascularization (CNV) is the growth of new, fragile blood vessels from the choroid layer into or beneath the retina. These vessels are the primary driver of severe vision loss in wet AMD. During fluorescein angiography, CNV appears as an area of hyperfluorescence, meaning it glows brightly in the photographs.
This brightness appears early in the test and expands in both size and intensity as the imaging continues. That expanding pattern distinguishes active CNV from areas of atrophy, which also appear bright early but do not grow beyond their original borders. Recognizing this difference is critical for selecting the right course of treatment.
The specific pattern of CNV seen on fluorescein angiography helps determine how your specialist will approach treatment. The images reveal whether the abnormal vessels sit directly beneath the center of the macula or off to the side. They also show the size and outer boundaries of the leaking area.
These details inform decisions about medication choice and injection frequency. Fluorescein angiography is also used to reassess the diagnosis when a patient is not responding as expected to treatment, helping to identify whether a different problem is contributing to ongoing vision changes.
OCT angiography (OCTA) is a newer, noninvasive imaging technique that can visualize blood flow without dye injection. While OCTA is a valuable tool in many situations, it has recognized limitations. For example, it can have difficulty imaging blood flow beneath pigment epithelial detachments, which are areas where the retinal pigment layer has lifted away from its base.
In certain complex cases, fluorescein angiography provides diagnostic information that OCTA and standard OCT cannot. Our specialists use all available imaging tools together to build the most complete picture of each patient's retinal health, choosing the right combination for each individual situation.
Who May Need Fluorescein Angiography
Not every patient with AMD will need fluorescein angiography at every visit. Our specialists recommend this test based on each patient's symptoms, examination findings, and overall clinical picture.
Fluorescein angiography is typically indicated when a patient with AMD experiences new vision loss, metamorphopsia (distorted or wavy vision), or a new scotoma (a blind or dark area in the visual field) that may signal the onset of wet AMD. Clinical signs that raise concern include elevation of the retinal pigment epithelium, bleeding beneath the retina, and exudate (fatty deposits from leaking blood vessels).
These symptoms and findings suggest that choroidal neovascularization may have developed and require prompt evaluation. Not all patients with wet AMD notice symptoms immediately, so careful examination is important even when a patient has not reported new visual complaints.
An estimated 18.34 million Americans have early AMD, and approximately 1.49 million have the late-stage form of the disease. AMD becomes more prevalent with advancing age, and additional risk factors include smoking, a family history of AMD, and certain genetic factors.
Our specialists may recommend fluorescein angiography for patients who show signs of transitioning from dry AMD toward the wet form, even before new symptoms appear. Early detection in this group can make a meaningful difference in preserving vision over the long term.
Anti-VEGF injections are medications that block a protein called vascular endothelial growth factor, which drives the abnormal blood vessel growth seen in wet AMD. When a patient receiving these injections does not show the expected improvement, fluorescein angiography can help identify why. The test may reveal persistent or recurring CNV, a different subtype of CNV than originally identified, or a separate condition contributing to the vision changes.
This information allows our team to adjust the treatment approach and pursue the strategy most likely to protect your remaining vision.
What to Expect During the Test
Fluorescein angiography is an outpatient procedure performed in our office. Understanding what happens at each stage can help make the experience more comfortable and reduce any uncertainty beforehand.
Our team will review your medical history and ask about any known allergies, particularly to dyes. Dilating eye drops will be placed in your eyes to widen the pupils, which allows a clearer view of the retina. Dilation typically takes about 20 to 30 minutes to reach full effect. You will then be seated in front of the angiography camera, which looks similar to other eye examination equipment you may have encountered.
We recommend bringing sunglasses to your appointment, since your eyes will remain sensitive to light for several hours after the test. You should also plan to have someone available to drive you home if your pupils are still dilated when you leave our office.
A technician will place a small needle into a vein in your arm or hand, similar to a standard blood draw. The fluorescein dye is then injected through this needle. Within seconds, the dye reaches the blood vessels in your eyes, and the camera begins capturing a rapid series of photographs as it flows through.
You may be asked to look in different directions so that all areas of the retina can be captured. Most patients notice a brief warm sensation when the dye is injected. The imaging process itself is not painful, though the initial needle stick may cause mild, momentary discomfort. The entire procedure generally takes about 10 minutes, with additional late-phase photographs sometimes taken several minutes afterward.
After the procedure, your skin may take on a slightly yellow tint for a few hours, and your urine will turn bright orange or yellow for one to two days. This is completely normal and simply means your body is clearing the dye. Drinking extra water after the test helps flush the fluorescein from your system more quickly.
Most patients can return to their regular activities the same day, aside from driving while their pupils remain dilated. Your specialist will review the images and discuss the results with you, often at the same visit or at a scheduled follow-up appointment.
Fluorescein angiography is generally well tolerated. The most common side effect is mild, temporary nausea, which occurs in a small percentage of patients and usually resolves quickly. Temporary skin and urine discoloration, as described above, are expected and cause no lasting harm.
Allergic reactions to the dye are rare but possible, ranging from minor hives to more significant responses. Before your test, please let our team know about any known allergies or previous reactions to fluorescein dye. Our staff is prepared and equipped to respond appropriately if any reaction occurs.
Fluorescein Angiography and AMD Treatment
Fluorescein angiography is not only a diagnostic tool. It plays a meaningful role throughout the course of AMD treatment, from the initial workup through longer-term follow-up care when needed.
Before beginning treatment for wet AMD, our specialists use fluorescein angiography to document the location, size, and type of choroidal neovascularization present. This initial angiogram serves as a reference point for measuring how the disease responds to treatment over time.
The baseline images also help guide medication selection. Currently approved anti-VEGF treatments for wet AMD include aflibercept (Eylea), ranibizumab (Lucentis), faricimab (Vabysmo), and brolucizumab (Beovu). Bevacizumab (Avastin), originally approved for cancer treatment, is also widely used for wet AMD in an off-label capacity. The specific angiographic findings can help inform which medication may be the most appropriate starting point for a given patient.
OCT has become the primary monitoring tool for most patients receiving anti-VEGF injections, because it is noninvasive and effective at detecting retinal fluid changes between appointments. For routine follow-up visits, OCT is often sufficient to determine whether the disease is stable or active.
When OCT findings are unclear or when a patient is not improving as expected, fluorescein angiography provides additional insight. It can reveal the source and extent of persistent leakage, identify new areas of CNV, or confirm that treatment has successfully closed the abnormal vessels. Both imaging approaches are recognized as valid and complementary tools for monitoring AMD treatment response.
Fluorescein angiography is not required at every visit. For many patients with wet AMD, the test may be performed at the time of initial diagnosis and then repeated only when there is a specific clinical reason, such as a sudden change in vision, an unexpected OCT finding, or lack of expected response to ongoing treatment.
As imaging technology continues to advance, fluorescein angiography remains a foundational diagnostic tool. Its ability to directly show dye leaking from abnormal blood vessels gives it a distinct clinical value that complementary technologies have not yet fully replaced.
When to Contact a Retina Specialist
Knowing when to seek care, and how urgently, is an important part of living with AMD. Our team is available to evaluate both urgent changes and ongoing concerns throughout your course of care.
Certain visual symptoms require immediate attention. If you experience a sudden increase in floaters (small moving shapes in your vision), flashes of light, a curtain or shadow spreading across your field of vision, or sudden vision loss in one eye, contact a retina specialist right away or go to the nearest emergency room. These symptoms may indicate a serious change in the retina that requires prompt evaluation and should not be waited on.
If you have been diagnosed with dry AMD and notice new or worsening distortion of straight lines, a dark or blank area in your central vision, or increasing difficulty reading even with your current glasses, contact a retina specialist promptly. Metamorphopsia, the perception that straight lines appear wavy or bent, is one of the earliest warning signs of developing choroidal neovascularization.
Early detection through timely fluorescein angiography and other diagnostic imaging gives treatment the best opportunity to protect your remaining vision.
If you are over age 50 and have risk factors for AMD, regular eye examinations are important. Your optometrist or general ophthalmologist can screen for early signs of AMD and refer you to a retinal specialist when needed. Patients already diagnosed with AMD in one eye face a higher risk of developing the condition in the other eye as well.
Using an Amsler grid at home, a simple card that displays a grid of straight lines with a central dot, can help you monitor your central vision between appointments. Any new distortion, missing areas, or waviness on the grid should be reported to your specialist without delay.
Frequently Asked Questions
Below are answers to questions our patients frequently ask about fluorescein angiography and how it fits into AMD care.
The test involves a needle stick in the arm to inject the dye, which may cause brief, mild discomfort similar to a routine blood draw. The imaging itself is not painful. Some patients notice a temporary warm sensation when the dye enters the bloodstream, and a small number experience brief, mild nausea. Both effects typically pass within minutes. Our team monitors you throughout the procedure and can address any concerns as they arise.
The frequency varies depending on your clinical situation and how your condition changes over time. Fluorescein angiography is most commonly performed at diagnosis and then repeated only when there is a clear clinical reason, such as a shift in symptoms, an inconclusive OCT result, or an unexpected treatment response. Some patients may go years between angiograms, while others may need the test more frequently if their disease is complex or changing. Your specialist will reassess the timing at each visit based on your current picture.
The test can reveal features of both forms, but it is most clinically valuable for diagnosing and classifying wet AMD. In dry AMD, the angiographic appearance remains relatively stable across the phases of the test, with areas of atrophy appearing as consistent bright spots that do not grow. In wet AMD, the test reveals the characteristic expanding leakage pattern that signals active CNV. For tracking stable dry AMD over time, OCT is typically the more practical and preferred monitoring tool in most clinical situations.
Most patients tolerate fluorescein angiography without difficulty. The most important consideration is a known allergy to fluorescein dye or a history of previous reactions. Patients with known allergies should tell our team before scheduling so that risk can be assessed and appropriate precautions considered. Patients who are pregnant should have a specific conversation with their specialist about whether the test is appropriate, since the safety profile of fluorescein dye during pregnancy has not been fully established. We will work with you to identify the safest diagnostic approach for your individual situation.
OCT and OCT angiography have taken over many routine monitoring functions because they are noninvasive and provide excellent information about retinal fluid and thickness. However, fluorescein angiography continues to offer information these tools cannot fully replicate, particularly regarding how blood vessels behave over the course of the test and the specific leakage characteristics of different CNV subtypes. Our specialists use both technologies as needed, selecting the approach that best answers the clinical question at hand. Neither technology has made the other obsolete.
Do not wait for your next scheduled visit if you notice sudden or significant changes in your vision. New distortion of straight lines, a dark spot in central vision, flashing lights, a sudden increase in floaters, or any unexplained visual change are all reasons to contact our office promptly or seek emergency care. In AMD management, timely evaluation of new symptoms plays a real role in treatment outcomes, and our team takes urgent concerns seriously.
Comprehensive AMD Care at New England Retina Associates
At New England Retina Associates, our fellowship-trained retinal specialists bring extensive experience in diagnosing and treating AMD at all stages, supported by advanced imaging technology and an active commitment to ongoing research. Whether you have been referred by your eye doctor or are seeking a second opinion, we are here to provide thorough, compassionate care and help you understand your diagnosis and all of your options. We welcome patients from across Connecticut and are ready to support you at every step of your AMD journey.
30 Years of Care & Commitment
